1515-89-5

Usage

Uses

Used in Pharmaceutical Industry:
1-Bromo-3-(methoxymethyl)benzene is used as a building block for the synthesis of various pharmaceuticals. Its unique structure allows for the creation of diverse medicinal compounds, contributing to the development of new drugs and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, 1-Bromo-3-(methoxymethyl)benzene serves as a key intermediate in the production of various agrochemicals. Its incorporation into these products helps enhance crop protection and management strategies.
Used in Dye and Pigment Production:
1-Bromo-3-(methoxymethyl)benzene is utilized as an intermediate in the manufacturing process of dyes and pigments. Its chemical properties enable the creation of a wide range of colorants used in various industries, including textiles, plastics, and printing inks.

Upstream product

• 823-78-9 meta-bromobenzyl bromide 
• 124-41-4 sodium methylate 
• 15852-73-0 (3-Bromophenyl)methanol 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 3132-99-8 m-bromobenzoic aldehyde 
• 77-78-1 dimethyl sulfate 
• 691-38-3 (Z)-4-methyl-2-pentene 

Downstream Products

• 67660-38-2 3,3'-Bis(bromomethyl)benzophenone 
• 67638-60-2 3,3'-Bis(methoxymethyl)benzophenone 
• 101763-98-8 S-(4-chlorophenyl) 3-bromobenzothioate 
• 1420836-81-2 C₁₉H₁₈O₃ 
• 1420837-19-9 C₂₀H₂₀O₃ 
• 142273-84-5 3-(methoxymethyl)phenylboronic acid 
• 675605-91-1 2-(3-(methoxymethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 119858-82-1 m-chloromethyl(methoxymethyl)benzene 
• 522622-95-3 3-(methoxymethyl)benzyl alcohol 
• 32194-76-6 3-methoxymethyl-benzoic acid 
• 69605-90-9 3-phenyl-benzyl alcohol 
• 160375-75-7 N⁶-cyclohexyl-5'-O-<(3-methoxymethylphenyl)diphenylmethyl>adenosine 
• 160375-71-3 1-(3-methoxymethylphenyl)-1,1-diphenylmethyl chloride 
• 261772-70-7 7-[(1R,2R,3R,5S)-3-(tert-Butyl-dimethyl-silanyloxy)-2-[(E)-(S)-3-(tert-butyl-dimethyl-silanyloxy)-4-(3-methoxymethyl-phenyl)-but-1-enyl]-5-(toluene-4-sulfonyloxy)-cyclopentyl]-heptanoic acid methyl ester 

Relevant academic research and scientific papers

Cobalt-Catalysed Reductive Etherification Using Phosphine Oxide Promoters under Hydroformylation Conditions

A phosphine-oxide-promoted, cobalt-catalysed reductive etherification using syngas as a reductant is reported. This novel methodology was successfully used to prepare a broad range of unsymmetrical ethers from various aldehydes and alcohols containing diverse functional groups, and was scaled-up to multigram scale under comparably mild conditions. Mechanistic experiments support an acetalization–hydrogenation sequence.

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

New method for the synthesis of benzyl alkyl ethers mediated by FeSO 4

The synthesis of benzyl alkyl ethers from benzyl bromides and alcohols using FeSO4 as a recoverable and reusable mediator has been described without use of base and cosolvent under mild conditions.

An improved synthesis of the selective EP4 receptor agonist ONO-4819

(Chemical Equation Presented) An improved synthesis of the highly selective EP4-receptor agonist ONO-4819 has been developed. The previous synthesis suffered from several drawbacks, in which a critical one is the difficulty in the removal of byproducts leading to unsatisfactory quality of the active pharmaceutical ingredient (API). Furthermore, on stereoselective reduction of an enone intermediate by binaphthol-modified lithium aluminum hydride, low concentration of the reaction conditions and tedious purification procedures to remove excess binaphthol were critical issues for the manufacturing process of the API. In the improved process,we have developed improved conditions using γ-thiobutyrolactone as sulfur source instead of potassium thioacetate to introduce the sulfur-containing C4 side chain without formation of byproducts. For stereoselective synthesis of the chiral alcohol, (-)-DIP-chloride reduction is found to be the best method, which can improve not only the enantioselectivity but also the workload for removing the chiral modifier in a purification process. Furthermore, benzoyl and tert-butyldimethylsilyl groups as protecting groups for hydroxyl functions were used for precise process controls of all intermediates. By changing these protecting groups, the purity of ONO-4819 was strictly controlled through crystalline intermediates. Thus, an improved robust process for ONO-4819 with a high chemical purity was developed. 2009 American Chemical Society.

2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF

The invention relates to pyrrolo pyrimidines of formula (I), wherein Y represents -(CH2)t-O- or -(CH2)r-S-, p is 1 or 2, r is 1, 2 or 3, t is 1, 2 or 3, or Y is -(CH2)j- or -CH=CH-, j is 1 or 2; p is 1 or 2, or Y is -(CH2)f-, f is 1 or 2, p is 1, and the further radicals and symbols have the meaning as defined herein; their preparation, their use as pharmaceuticals, pharmaceutical compositions containing them, the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment of neuropathic pain and to a method for the treatment of such a disease in animals, especially in humans.

5-thia-ω-substituted phenyl-prostaglandin E derivatives, process for producing the same and drugs containing the same as the active ingredient

The present invention relates to 5-thia-ω-substituted phenylprostaglandin E derivatives of the formula (I) (wherein, all the symbols are as defined in the specification), process for producing them and pharmaceutical compositions comprising them as active

γ(v)-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT

An ω-substituted phenyl-prostaglandin derivative of formula (I), a process for the preparation thereof, a medicament comprising it as active ingredient (all symbols have the same meaning as described in the specification). The compounds of the formula (I)

3,7-dithiaprostanoic acid derivative

A 3,7-dithiaprostanoic acid derivative of the formula (I) STR1 (wherein, R1 is OH, C16 alkyloxy, NR6 R7 (R6, R7 are H, C16 alkyl.); R2 is H, OH; R3 is single bond, C16 alkylene; R4 is (i) C18 alkyl substituted by C16 alkyloxy, halogen etc., (ii) phenyloxy